The clinical outcome of patients carrying MLL-rearrangement who often suffer from either failure of induction therapy or disease relapse remains extremely poor, while the response rate reported in adult MLL-rearranged (MLL-r) AML is approximately 40% [8]. Here, KMT2A is linked to acute myeloid leukemia.